...by Allergan Inc. Allen, who worked with Hatfield at Zafgen Inc., was VP of finance at Alnylam Pharmaceuticals Inc....

...general manager for several European countries at Alnylam Pharmaceuticals Inc....

...By BioCentury Staff Alnylam’s vutrisiran meets Phase III amyloidosis endpointAlnylam Pharmaceuticals Inc. (NASDAQ:ALNY) will submit an...
...patients. Comments are due April 6.TARGETSIL-23 – Interleukin-23TTR – Transthyretin BC Staff vutrisiran (ALN-TTRsc02) Skyrizi, risankizumab (ABBV-066, BI 655066) Alnylam Pharmaceuticals Inc. AbbVie U.S...

...meetings. FDA approved siRNA therapy Oxlumo lumasiran from Alnylam Pharmaceuticals Inc....

...down from his role as EVP, CMC and continue as an executive adviser to the CEO.Alnylam Pharmaceuticals Inc....

...By Jeff Cranmer, Executive Editor Alnylam and Millennium...
...John Maraganore for 17 years to build Alnylam Pharmaceuticals Inc....
...president four years later.  Maraganore and Greene established Alnylam’s...

...month’s FDA approval of Oxlumo lumasiran from Alnylam Pharmaceuticals Inc....

...in the life sciences.” Maraganore is CEO of Alnylam Pharmaceuticals Inc....
...by life sciences companies and their leaders. Steve Usdin Genzyme Sanofi Alnylam Pharmaceuticals Inc. Henri...

...unstable angina requiring hospitalization in adults with established cardiovascular disease.Leqvio inclisiran, an siRNA against PCSK9 from Alnylam Pharmaceuticals Inc....

...approval of Oxlumo to treat primary hyperoxaluria, Alnylam...
...many years for an RNAi therapy from Alnylam Pharmaceuticals Inc....
...for payers that arise with the new therapy. Alnylam...